Publication date: Jul 10, 2019
Dr Sadakatsu Ikeda speaks to ecancer at the WIN 2019 Symposium in Paris about the rapidly changing landscape of precision medicine in Japan.
He explains that there has been recent approval for access to comprehensive genomic profiling in Japan, with between 5000 and 20,000 people per year expected to be available for this data capture.
Dr Ikeda also discusses the difficulties in accessing drugs following genomic sequencing due to the possible treatments being ‘off-label’.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
- i2b2 tranSMART Foundation Harvard Symposium 2019 – Personalized Medicine
- i2b2 tranSMART Foundation Harvard Symposium 2019 – tranSMART Update
- Organizing the world’s variant data for genomic medicine with Mark Kiel | Talking Precision Medicine #12
- Dr. Michael Astion and PLUGS – a Laboratory Stewardship Program to Foster Precision Medicine Best Practices
- Moderated Discussion: Personalized genomics: a direct-to-patient approach
- Drug Development Panel – 2019 Stanford Medicine Big Data | Precision Health
- Dr. Leroy Hood. Systems Medicine: Integration of Biology, Computation and Technology
- i2b2 tranSMART Foundation Harvard Symposium 2019 – MedCo: Enabling the Secure and Privacy-Presering Exploration of Distributed Clinical and *Omics Data
- NGS Target Enrichment Solutions to Drive Discovery in Precision Medicine Research
- Precision Medicine Webinar Training May 2019
- Precise DNA Sequencing: A Necessity for Precision Medicine
- AI in the Clinic Panel – 2019 Stanford Medicine Big Data | Precision Health